ROCHESTER, Minn. — A study published in Gastroenterology finds that radiomics-based machine learning models may detect pancreatic cancer on prediagnostic CT scans substantially earlier than current methods for clinical diagnosis.
“Pancreatic cancer is a deadly disease and a leading cause of cancer-related death,” says Ajit Goenka, M.D., a Mayo Clinic diagnostic radiologist and the study’s senior author.
Dr. Goenka says that while early detection enhances the chances for successful treatment, standard imaging cannot detect early pancreatic cancer.
“Up to 40% of small pancreas cancers may not show up on standard imaging. As a result, the majority of patients present with advanced and noncurable disease,” says Dr. Goenka.
For this reason, Dr. Goenka and his colleagues looked to incorporate artificial intelligence (AI) into radiological screening to detect pancreatic cancer at an earlier, more curable state. “We found that AI models can detect cancer from a normal-appearing pancreas on CTs several months prior to cancer symptoms, even when the disease was beyond the scope of perception of radiologists.”
For the study, researchers computationally extracted the imaging signature of early cancer from CTs. Prediagnostic CTs are CTs that were done for unrelated indications between three months and three years prior to cancer occurrence.
Next, they used an age-matched group of control subjects who did not develop pancreatic cancer during three years of follow-up. Expert radiologists then segmented the pancreas on CTs from both groups and computationally extracted and quantified the metrics of pancreas tissue heterogeneity.
Next, researchers built advanced machine learning models that could predict the future risk of pancreatic cancer at a median time of 386 days, a range of 97 to 1,092 days, prior to clinical diagnosis with accuracies that ranged from 94% to 98%.
“In comparison, radiologists were unable to reliably differentiate between patients who went on to develop cancer versus those who had normal pancreas,” says Sovan Mukherjee, Ph.D., a senior data science analyst in Dr. Goenka’s team and the study’s first author. “We also tested our AI models against variations in image noise, scanner models, image acquisition protocols and postprocessing parameters, and found them to be unaffected by these variations.”
Dr. Goenka says this level of testing is necessary for the potential deployment of this technology in clinical practice. Finally, researchers validated the high specificity — 96.2% — of the AI model on an open-source CT data set to further increase the reliability of the AI methodology.
“Our study demonstrates that artificial intelligence can identify those asymptomatic people who may harbor an occult cancer at a stage when surgical cure may be possible,” says Dr. Goenka. “These findings may help overcome one of the key barriers to improving survival for patients with pancreatic cancer.”
Dr. Goenka says a large prospective clinical trial — the Early Detection Initiative (NCT04662879) sponsored by the Pancreatic Cancer Action Network — is underway to evaluate the impact of a pancreatic cancer screening strategy using CTs in 12,500 participants. The trial is being led by Suresh Chari, M.D., an emeritus Mayo Clinic gastroenterologist. Dr. Goenka’s team is exploring the option of prospective validation of their AI models on the CTs to be done as part of the EDI trial.
Co-authors are Dr. Mukherjee, Panagiotis Korfiatis, Ph.D., Garima Suman, M.D., Shounak Majumder, M.D., Matthew P. Johnson, Nicholas Larson, Ph.D., Darryl Wright, Ph.D., Timothy Kline, Ph.D., Joel G. Fletcher, M.D., and Dr. Chari, all of Mayo Clinic; as well as Anurima Patra, M.D., Hala Khasawneh, M.D., Naveen Rajamohan, M.D., and Ananya Panda, M.B.B.S., who were at Mayo Clinic at the time of this research.
The authors gratefully acknowledge funding from the Centene Charitable Foundation, Champions for Hope Pancreatic Cancer Research Program of the Funk Zitiello Foundation, and the National Cancer Institute.
###
About Mayo Clinic Comprehensive Cancer Center
Designated as a comprehensive cancer center by the National Cancer Institute, Mayo Clinic Comprehensive Cancer Center is defining new boundaries in possibility, focusing on patient-centered care, developing novel treatments, training future generations of cancer experts, and bringing cancer research to communities. At Mayo Clinic Comprehensive Cancer Center, a culture of innovation and collaboration is driving research breakthroughs that are changing approaches to cancer prevention, screening and treatment, and improving the lives of cancer survivors.
About Mayo Clinic
Mayo Clinic is a nonprofit organization committed to innovation in clinical practice, education and research, and providing compassion, expertise and answers to everyone who needs healing. Visit the Mayo Clinic News Network for additional Mayo Clinic news.
